Plan to attend the 25th Anniversary Congress of the ESGCT in Berlin on the 17th to 20th of October?
Delphi Genetics will be there along with stunning news.
Meet us at the BOOTH#37
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines
Delphi Genetics receives GMP certification for plasmid DNA bioproduction
The GMP production will benefit from the ‘Antibiotic Free Technology’
Gosselies – Charleroi, Belgium – 11 July 2017
Delphi Genetics, a company specialized in genetic engineering, is very pleased to announce that it has just received the certificate of Good Manufacturing Practice (GMP) for plasmid DNA production. The GMP productions will be realized in clean rooms located in Delphi Genetics’ own facilities.
Following the GMP audit and approval by AFMPS, the strict Federal Agency for Medicines and Health Products, Delphi Genetics will be allowed to produce plasmid
Delphi Genetics will be part of the Belgian delegation to the BIO 2017 international convention in San Diego, USA, from June 19 to 22. You can either visit us at the Belgian booth or meet us during the partnering sessions. Don’t hesitate to contact us through our website www.delphigenetics.com or the BIO 2017 website, section “partnering”. See you there! Kind regards.
Meet Delphi Genetics at the “Cell & Gene Therapy” conference on March 27 & 28 in Madrid Spain. Delphi Genetics will be an exhibitor at this conference, join us at the booth!
Delphi Genetics will be an active participant at the Buzz4Bio event “Bioproduction Vol.6”. Meet us at our booth in the exhibition hall during these two days and/or attend our presentation on “Antibiotic Free” bioproduction on Friday February 3.
Delphi Genetics will take part of the BIO-Europe 2016 event in Cologne this year. You can either meet us during the partnering sessions or on specific appointments on the Belgian booth. If interested please contact us through our website www.delphigenetics.com or through the Bio-Europe 2016 website / “partnering” section. See you there! Kind regards.
To sustain the strong growth of its activities and the development of its services, including pDNA GMP production in the near future, Delphi Genetics is hiring a Key Account Manager Europe (M/F) to cover the following countries: UK, Scandinavian Countries, The Netherlands, Germany and Central Europe
Delphi Genetics is an expert company in genetic engineering and bioproductions. The company provides services based on unique technologies (Staby®). With a core business in plasmid DNA development and applications, Delphi Genetics is a partner of choice for Biotech & Pharmaceutical companies requiring bioproductions.
Today Delphi Genetics was highlighted by the Biotech specialized website “labiotech.eu”! Please use the following link to see the article : “How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics”: http://labiotech.eu/antibiotics-free-bioproduction-delphi-genetics/
Delphi Genetics will take part of the BIO Spain 2016 international event in Bilbao this year. You can either meet us during the partnering sessions or on specific appointments. If interested please contact us through our website www.delphigenetics.com or through the Bio Spain 2016 website “partnering” section. See you there! Kind regards.
Afin d’accompagner la croissance forte de ses activités et le dévelopement important de ses prestations de service, Delphi Genetics recrute un(e) technologue de laboratoire pour un travail de biologie moléculaire et de culture cellulaire. Veuillez envoyer votre CV complet et lettre de motivation à l’attention de Mme Charline Savels : email@example.com
Basée sur ses technologies de production de protéines recombinantes et d’ADN, Delphi Genetics développe et preste des services pour les sociétés actives dans le domaine des biotechnologies, de la pharmacie et du diagnostic. Delphi Genetics est localisée dans le Biopark de Gosselies
Delphi Genetics SA announced today an important step in the implementation of its new strategic orientation, investing in new DNA GMP facilities in its recently built offices located at the BioPark of Charleroi (Gosselies).
Delphi Genetics has announced that it has recently secured financing totalling 3.4 Million EUR for its new developments. The financing consists in a bank investment credit in the amount of 2.5 Million EUR granted in order to finance its building and production facilities and a funding by the Walloon Region in the amount of 0.93 Million EUR, as
Delphi Genetics will be part of the Belgian delegation to BIO 2016 international convention in San Francisco, US from June 6 to 9. You can either visit us at the Belgian booth or meet us during the partnering session.
Delphi Genetics will attend the spring meeting of the International Society for Bioprocess Technology in Washington (from March, 7 to March 9, 2016). The meeting will be focused on Viral vectors & vaccines, Cellular therapies and Baculovirus expression technology.
Delphi genetics will attend the Lipinov meeting in Paris on November 23 and 24. This meeting will gather French researchers and industries involved in lipase production. Delphi Genetics will be present with a stand.
Delphi Genetics will be present at Bio Europe 2015 in Munich on November 2 to 4.
BIO-Europe® is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain,
Delphi Genetics will be part of the Belgian delegation to BIO 2015 international convention in Philadelphia, US from June 15 to 18. You can visit us at the Belgian booth.
Delphi Genetics SA announced today the closing of a capital increase in excess of 1 Million EUR to support its latest development in “Good Manufacturing Practices (GMP)” services for protein and DNA productions, especially engineered for small/medium scale needs. Equity funds were provided by lead investors Sambrinvest (a venture capital fund active in Charleroi/Thuin area) and Invest4 DelphiG2 (Mr. François Blondel and Dr. Philippe Janssens de Varebeke), together with the two managing directors of the company, Mr. Michel Milinkovitch and ULB (Université Libre de Bruxelles) through its fund Theodorus SCA.
Delphi Genetics will collaborate with Avaxia Biologics (Lexington, Massachusetts) for the development of efficient antibodies against TNF. “It is a very exciting project that perfectly synergizes with the existing developments of Delphi Genetics. Moreover, it will strengthen our activities using our Staby® technology for the production of DNA and proteins at high yield and without antibiotic resistance genes. The collaboration with Avaxia is a very good opportunity for us to translate our technological expertise into concrete projects with future commercialization potential. Of course, we hope that this project will be